Navigation Links
Genomic Health Announces Management Changes and New Responsibilities
Date:1/8/2009

REDWOOD CITY, Calif., Jan. 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the appointment of Kimberly J. Popovits as chief executive officer. Formerly president and chief operating officer, Popovits is now the president and CEO of Genomic Health. In addition, G. Bradley Cole has been appointed as chief operating officer and will continue to serve as the company's chief financial officer, reporting to Popovits.

"Kim's appointment as CEO reflects her unique experience and passion to lead all aspects of our business, as I turn my focus to the longer-term strategy and vision of the organization. This transition marks an important milestone for the company, reflecting our leadership and success in delivering personalized medicine to patients," said Randy Scott, chairman of Genomic Health. "Brad's increasing responsibility as COO recognizes his contribution to the operations of the company and further strengthens our ability to deliver our services to physicians and patients around the world. I look forward to working with Kim, Brad and our entire management team as we continue our efforts to expand worldwide commercialization of the Oncotype DX breast cancer assay, advance our research and development pipeline, and move the organization toward profitability."

In addition to Scott, Popovits and Cole, members of the Genomic Health management team include Steve Shak, chief medical officer; Joffre Baker, chief scientific officer; David Logan, senior vice president of worldwide commercialization; Tricia Tomlinson, senior vice president of human resources; and Laura Leber, vice president of corporate communications.

Prior to her appointment as president and CEO, Popovits served as president and COO since joining Genomic Health in February 2002, and as a director since Mar
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
2. Genomic Health Announces Study Establishing the Utility of Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated with Aromatase Inhibitors
3. Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology
4. Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
6. UC San Diego to lead nationwide program in pharmacogenomics
7. NeoGenomics to Present at the Noble Financial Equity Conference
8. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
9. Genomic Health to Announce Second Quarter 2008 Financial Results and Host Conference Call on Tuesday, August 5, 2008
10. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
11. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Vitals, a recognized and trusted ... Fabi of Cosmetic Laser Dermatology one of their Top ... of patients to share their doctor experiences and rate their ... time, and follow-ups. The Vitals Top 10 Doctor recognition means ... was ranked one of the highest by patients. , “I’m ...
(Date:8/28/2014)... 2014 Altec Products, Inc., a ... announced today that they have been awarded the ... of the International Association of Microsoft Channel Partners ... founded in 1994, providing Microsoft Partners with a ... community at large while facilitating mutual growth and ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The Baltimore ... web design firms in Baltimore and awarded The ... on 2013 revenue from Web design, The Canton Group ... The Canton Group’s clients include Fortune 1000, higher education, ... organizations. The Canton Group specializes in web design and ...
(Date:8/28/2014)... 28, 2014 Postcard-worthy views, star-laden skies, ... glamping by the beach in your own private bungalow ... Palmar at the Islands of Loreto. , The newest ... unforgettable experience in paradise with its romantic Honeymoon package, ... 2014. , “Villa del Palmar at the Islands of ...
(Date:8/28/2014)... Labor Day weekend typically conjures up images ... glorious glimpses of summer. However, more of Dr. ... their long weekend recovering from a quick cosmetic procedure. ... plastic and reconstructive surgeon based out of Newport Beach, ... their holiday weekends to do something for themselves. ...
Breaking Medicine News(10 mins):Health News:Dr. Sabrina Fabi of Cosmetic Laser Dermatology Recognized as Vitals Top 10 Doctor 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 3Health News:The Canton Group is Recognized by the Baltimore Business Journal as the Largest Web Design Firm in Baltimore 2Health News:Honeymoon in Paradise at Villa del Palmar at the Islands of Loreto 2Health News:Honeymoon in Paradise at Villa del Palmar at the Islands of Loreto 3Health News:Honeymoon in Paradise at Villa del Palmar at the Islands of Loreto 4Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 3Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 4
... New research challenges the previously held belief that infants' ... new study finds the brain's left hemisphere plays the ... immediately after birth. ,Researchers are using functional ... activity in response to speech. They say this is ...
... try to avoid getting it, but researchers say common cold ... genetically engineer the common cold virus so that //it kills ... They did this by modifying one gene, so the virus ... the activity of another gene to ensure that the virus ...
... Government guidelines on the treatment of asthma have long ... for people with persistent forms of the condition.But reports ... people -- including parents of asthmatic children -- to ... growth retardation in children, weak bones in children and ...
... therapeutic option for patients with complicated type 1 diabetes, ... // Now, a new study finds ... worse survival than patients on the transplant waiting list ... Association supports a pancreatic transplant for patients who have ...
... a vaccine made from the common cold virus may induce ... the Centers for Disease Control and Prevention injected six monkeys ... parts of the SARS coronavirus. A new form of the ... were given a second vaccine 28 days later, and researchers ...
... women with diabetes have a higher risk of depression., ... 60 and 79. The participants were divided //into two ... the second included those without diabetes. Women who did ... groups, based on their levels of insulin resistance. ...
Cached Medicine News:Health News:New Technique to Study Infants Brain. 2Health News:Benefits and Risks of Asthma Treatment Questioned 2Health News:Pancreas Transplant for Diabetics 2
(Date:8/28/2014)... Md. , Aug. 28, 2014 ... of novel anti-infective biologic and drug candidates targeting ... and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced ... phase of cGMP manufacturing of SYN-004, Synthetic Biologics, ... Clostridium difficile ( C. difficile ) ...
(Date:8/28/2014)... 28, 2014 Today is the official launch ... higher education, student and pharmaceutical organizations that will work ... ADHD prescription stimulant medication. The Coalition will initially focus ... reported rates of nonmedical use vary, a 2013 study ... 1 of college students reported nonmedical use of ...
(Date:8/27/2014)... 27, 2014 TWi Pharmaceuticals, Inc. (4180.TT) today ... the United States Food and Drug Administration (FDA) ... megestrol acetate 125mg/ml oral suspension, the generic equivalent ... first-to-file and under Hatch Waxman rules, it will ...  TWi has completed the pre-launch preparation of the ...
Breaking Medicine Technology:Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 2New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 3New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 4New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 5New Coalition Aims to Help Prevent Misuse, Abuse and Diversion of ADHD Medications 6TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2
... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
...  In conjunction with its first quarter 2012 earnings release (expected to be ... CVD ) is pleased to invite you to listen to its ... on Thursday, May 3, 2012 at 9:00 a.m. ET. , ... and Slide Presentation , , , , When: , , , ...
Cached Medicine Technology:American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
... GV is a sterile, non-pyrogenic, transparent ... noninflammatory, high molecular weight (average = ... hyaluronate. Healon GV contains 14 mg/mL ... a physiological sodium chloride-phosphate buffer (pH ...
... PROVISC ophthalmic viscosurgical device ... is characterized by high molecular ... surface tension. It provides excellent ... and is easily removed. It ...
... a product comes along that forever raises ... category. The new StealthStation TREON plus Treatment ... Built on the phenomenal success of the ... system in the worldthe new TREON plus ...
... the DigiCat Imager ("DCI") to provide rapid, ... The DCI can measure the cataract and ... objective, appropriate and timely surgical decision can ... technology is especially useful in todays healthcare ...
Medicine Products: